Clinical TrialPlaceboKetaminePlaceboCompleted

Sub-Anaesthetic Ketamine at C-Section to Prevent Postpartum Depression: Double-Blind RCT (Alipoor / Sarkoohi, Rafsanjan Iran 2021)

Double-blind, randomised clinical trial of sub-anaesthetic ketamine vs placebo administered at the time of elective caesarean section for prevention of postpartum depression (J Med Life 2021 Jan-Mar; Alipoor M, Loripoor M, Kazemi M, Farahbakhsh F, Sarkoohi A; Rafsanjan University of Medical Sciences, Iran; PMID 33767791; DOI 10.25122/jml-2020-0116). Participants: pregnant women aged 18–35, elective C-section, ASA class 1/2, low-risk pregnancy, no history of underlying disease or drug abuse. Exclusions: post-delivery haemorrhage requiring transfusion, withdrawal of consent. n=67 analysed (sample size calculation originally ~35/arm). Intervention: ketamine IV (sub-anaesthetic dose) at induction vs saline placebo. Primary outcome: postpartum depression assessed by standardised scale (EPDS or HDRS) at postpartum follow-up. No CT.gov registration; no DataBankList; no IRCT number found in abstract text. Iranian clinical trial registries (IRCT) not searchable via CT.gov.

Target Enrollment
70 participants
Study Type
interventional
Design
Randomized, double Blind

Study Arms & Interventions

Intervention group

experimental

Receives Nesdonal and ketamine during the induction of anesthesia

Interventions

  • Placebo1.5 mg/kg
    via IVsingle dose1 doses total

    Dose range 1-2 mg/kg

  • Ketamine0.5 mg/kg
    via IVsingle dose1 doses total

    Administered during induction of anesthesia

Control group

active comparator

Receives only Nesdonal during the induction of anesthesia

Interventions

  • Placebo4 mg/kg
    via IVsingle dose1 doses total

    Dose range 3-5 mg/kg

Primary Results(1 publication)

Participants

N = 134Mean age: 27.4–28.24 across armsM. et al. 2021

Adverse Events (from all publications)

Arm / GroupnAny TEAESevereSeriousDiscont.
Intervention groupexperimental67
Control groupactive_comparator67

* No treatment-emergent adverse events (TEAEs) or other safety outcomes for the mothers were reported in the paper. The paper discusses Apgar scores for neonates, but these are not maternal safety outcomes.

Study Details

  • Status
    Completed
  • Type
    interventional
  • Design
    Randomizeddouble Blind
  • Target Enrollment70 participants
  • Timeline
    Start: 2019-01-01
    End: 2021-01-01
  • Compounds

Related Publications

Your Library